HOUSTON, October 2 — GT Medical Technologies announced on September 29, 2026, that the results of the randomized, multicenter ROADS trial (NCT04365374) were published as a Rapid Communication in the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology.
The trial showed that patients with newly diagnosed operable brain metastases who received tumor removal surgery followed by GammaTile® cesium-131 collagen tile-based radiation therapy experienced lower local tumor recurrence and significantly longer overall survival compared to the standard-of-care approach of surgery followed by post-operative stereotactic radiation therapy. Study authors concluded that GammaTile should be considered a standard-of-care option for this patient population.
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with four cesium-131 radiation sources, placed directly in the surgical cavity at the time of tumor removal, enabling immediate radiation delivery. In contrast, the current standard-of-care involves surgery followed by post-operative SRT administered weeks later after surgical recovery. The ROADS trial found that 17.8% of patients in the standard-of-care arm did not receive their prescribed post-operative SRT, consistent with published data indicating 20-27% of patients fail to complete the full course of post-operative SRT, highlighting a limitation of the delayed radiation approach.
Because GammaTile delivers radiation immediately at surgery, it eliminates the risk of non-delivery due to treatment delays or incompleteness. Even when the analysis was restricted to patients who received their prescribed radiation in each arm, GammaTile maintained superiority in local tumor control and surgical bed recurrence-free survival.
The study’s co-lead investigator, Jeffrey Weinberg, MD, professor of Neurosurgery at The University of Texas MD Anderson Cancer Center, stated that TBRT closes the gap between resection and radiation, providing patients with certainty from day one. Corresponding author Thomas H. Beckham, MD, PhD, Associate Professor of CNS Radiation Oncology at MD Anderson, noted that the benefit of TBRT extends beyond improved treatment completion to intrinsic efficacy in tumor control.
The publication in JCO underscores the clinical and potential economic significance of GammaTile as a practice-changing advancement in brain metastases management.
